You searched for "evidence"
RSM: Andrology update 2026: advances across benign and oncological practice
Why attend? Hear from leading experts including Professor Axel Heidenreich, Professor Robert Huddart, Professor Vaibhav Modgil and Professor Nicholas Watkin Gain updates on advances in erectile dysfunction management, Peyronie’s disease and other benign andrological conditions Gain an up-to-date understanding of...RSM: Urothelial cancer: advances, innovation and improving outcomes
Why attend? Hear from leading experts including Professor Param Mariappan, Professor Tom Powles, Professor Ben Challacombe and Professor Alison Birtle Explore how quality improvement initiatives, including lessons from Scotland's bladder cancer KPI programme, are shaping care delivery. Gain updates on...
Cost effectiveness of prostate cancer screening in Europe
Prostate cancer (PCa) stands as the most prevalent cancer and the third leading cause of cancer-related deaths among men in Europe. According to data from the European Commission, in 2020, PCa represented a staggering 23.2% of all new cancer cases...A guide to local anaesthetic transperineal prostate biopsy
In the UK, nearly 100,000 men undergo a prostate biopsy annually, a figure projected to double in the next decade [1]. In recent years, we have observed a paradigm shift in urological practice in numerous UK hospitals. The conventional transrectal,...Prolapse surgery with mesh: where do we stand in 2017? An ICS update
Background Surgery for pelvic organ prolapse (POP) is common among women. The lifetime risk of undergoing at least one surgical procedure for POP is up to 20% [1]. This kind of surgery will be increasingly important due to an ageing...Micro-Ultrasound in Prostate Cancer: Diagnosis, risk stratification, and active surveillance
Prostate cancer diagnostics have undergone a major shift with the adoption of multiparametric MRI (mpMRI), improving detection of clinically significant disease while reducing unnecessary biopsies [1,2]. However, MRI-based pathways come with practical limitations: cost, access, delays and reliance on radiological...
The role of continuous prophylactic antibiotics following JJ stent insertion
Urinary tract infections (UTI) and stent-related symptoms (SRS) are frequently recognised complications of ureteric stent placement. Antibiotic administration at induction prior to ureteric stent insertion is recommended by the European Association of Urology (EAU). Commencing prophylactic antibiotics for the ‘entire...
Ulcerative colitis has a positive association with prostate cancer risk
This large-scale meta-analysis, incorporating studies from several population-based studies, evaluated the association between inflammatory bowel disease (IBC) and prostate cancer (Pca). Emerging evidence has suggested that IBD is a risk factor for extra-intestinal malignancies which may be due to an...
Cardiac failure and medical therapy for LUTS / BPH
Alpha blockers (AB), 5-alpha reductase inhibitors (5-ARI) and combination therapy are widely prescribed for lower urinary tract symptoms (LUTS) considered consequent to prostatic enlargement and are the mainstay of first-line therapy. This retrospective interrogation of a large population-based dataset of...
Risk factors for BC after minimally invasive RNU
Bladder cancer (BC) after radical nephroureterectomy (RNU) has an approximate incidence of 20-50%. This contemporary multicentre study will inform the ongoing debate on risk factors for BC after minimally invasive RNU and how it may be prevented. Three hundred and...
Association of prostate size with capsule thickness and glandular epithelial cell density
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two significant urologic diseases affecting ageing men. BPH is histologically evident in over half of men above 50, while PCa is a highly lethal cancer prevalent in men in the United...
